AMG220
Recombinant proteinexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2006 (NCT00353756)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-6 receptor alpha subunitINHIBITOR
IL6R inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- c326
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00353756 | Phase 1 | Sep 1, 2006 | Avidia, Monash University, University of Queensland |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Avidia | For profit | 1 | 1 | 1 | 2006 |
| Monash University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Queensland | Academic/Hospital | 1 | 0 | 1 | 2006 |
3 organizations
Page 1 / 1